On October 30, 2023 Fosun Pharma reported its 2023 Third quarterly report (Filing, 3 mnth, SEP 30, Fosun Pharma, 2023, OCT 30, 2023, View Source [SID1234639227]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 30, 2023 NEC reported its consolidated Financial Results for the six months ended September 30, 2023 (Press release, NEC, OCT 30, 2023, https://pdf.irpocket.com/C8793/MH4b/MZCP/o67J.pdf [SID1234639212]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 31, 2023 Leroy Hood, MD, PhD, co-founder of Seattle’s Institute for Systems Biology (ISB) and a pioneer in systems biology, and Rebecca Lambert, founder and CEO of NED Biosystems, Inc. (NED), a public benefit corporation that is developing the first oral "systems treatment" for cancer, reported to have entered into a memorandum of understanding to collaborate on a clinical trial to show how cancer’s onset may be reversed (Press release, NED Biosystems, OCT 30, 2023, View Source [SID1234636544]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NED’s cancer treatment, NED-170, takes a systems approach that combines repurposed, oral agents that are well documented in humans to affect critical cancer disease-driver processes at doses that lack customary toxicity and side effects.

"A systems biology approach is paramount – NED-170 is the multi-pronged treatment required to subvert cancer’s complex system," said Hood, who is inventor of the DNA Sequencer, technology which enabled the Human Genome Project.

The collaborative trial’s objective is to gather intelligence through a multi-dimensional monitoring of the tissue in which a tumor grows. A simple blood test utilizes the latest ultra-sensitive hyper-personalized proteomics technologies to measure the traces of more than 3,000 distinct proteins at once that reveal many processes in the tumor tissue, thereby offering an assessment of the specific efficacy of the individual agents in the multi-pronged approach.

NED-170’s Phase 1b/2 clinical trial is designed to treat patients concomitant to standard of care who lack an option for targeted therapy based on tumor genome sequencing in three indications representing large unmet needs: cholangiocarcinoma, triple negative breast cancer, and ovarian cancer.

NED is initially targeting the 50 percent to 80 percent of cancer patients whose tumors do not carry mutations for targeted therapy. Based on observational data, NED believes its systems treatment, when combined with standard of care therapies, may afford patients extended survival and enhanced quality of life. The data collected from NED’s initial trial and follow-on clinical trials will serve to develop a database for ISB’s large study utilizing proteomics and NED-170 to optimize the systems approach for suppression of cancer progression based on the driver processes in subclasses of patients.

"A truly comprehensive approach to a complex adaptive system like cancer, as the war on global terror has taught us, must be a multi-pronged approach that moderates, without adding stress, the various behaviors that promote cancer and allows the tissue to re-establish the balance of a normal cell community," said Sui Huang, MD, PhD, and ISB professor, cancer cell dynamics expert, and NED Biosystems Systems Advocate.

The envisioned high-dimensional profiling of a patient’s blood biochemistry baseline can inform doctors about how the tumor bed is preparing a tiny tumor for outgrowth before a tumor is clinically detectable, which can be different in different patients. It can also tell us precisely which biological processes a particular tumor relies on most to (re)grow in a given patient. Uncommon quality of life improvements (and cost savings) may be achieved when a cancer patient is treated with evidence-based agents efficacious against key pathways at doses that lack toxicity and side effects.

"By moderating multiple cancer progressing pathways and cancer stem cells at once, NED-170 affords a comprehensive systems approach never before available to cancer patients," said Lambert. "The comprehensive blood profiling utilized to measure NED-170’s impact on pathways advances a personalized measurement of each patient’s unique cancer signature."

On October 30, 2023 Enable Medicine, a leader in AI for biological research and drug discovery, reported that it will present a number of poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting being held November 1-5, 2023, in San Diego, California (Press release, Enable Medicine, OCT 30, 2023, View Source [SID1234636472]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These study results will advance our understanding of the tumor microenvironment and empower researchers to use our comprehensive maps of disease biology to understand how the organization of cells impact disease pathology, progression, and therapeutic response."

Post this
Title: From images to insights: Deep spatial profiling reveals disease and treatment biomarkers
Abstract Number: #95
Date / Time: November 3rd, 12–1:30 p.m. PDT & November 4th, 11:55–1:25 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: Integrative spatial multi-omics analysis of NSCLC tumor microenvironment identifies key features associated with response to immune checkpoint inhibitor therapy
Abstract Number: #222
Date / Time: November 3rd, 12–1:30 p.m. PDT & November 4th, 11:55–1:25 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Poster presentation details:
Title: emObject: domain specific data abstraction for spatial omics
Abstract Number: #899
Date / Time: November 3rd, 12–1:30 p.m. PDT & November 4th, 11:55–1:25 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: Quantitative cell morphology featurization in multiplexed immunofluorescence images reveals tumor subtypes in cancer microenvironments
Abstract Number: #1290
Date / Time: November 3rd, 12–1:30 p.m. PDT & November 4th, 11:55–1:25 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: A machine learning toolkit for automated processing of multiplexed immunofluorescence images
Abstract Number: #1302
Date / Time: November 3rd, 12–1:30 p.m. PDT & November 4th, 11:55–1:25 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: Polarity measurements from multiplex imaging suggest immune cell activation
Abstract Number: #1314
Date / Time: November 3rd, 12–1:30 p.m. PDT & November 4th, 11:55–1:25 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

Title: Identification and generalization of tissue structures with spatial cellular graph partitioning
Abstract Number: #1315
Date / Time: November 3rd, 12–1:30 p.m. PDT & November 4th, 11:55–1:25 p.m. PDT
Location: Exhibit Halls A and B1 – San Diego Convention Center

"We are excited to showcase the capabilities of Enable Medicine’s platform in analyzing pathology and other omic data to improve our understanding of cancer biology and predict potential treatment response in patients," said Sunil Bodapati, CEO, Enable Medicine. "These study results will advance our understanding of the tumor microenvironment and empower researchers to use our comprehensive maps of disease biology to understand how the organization of cells impact disease pathology, progression, and therapeutic response."

The full abstracts will be released on the SITC (Free SITC Whitepaper) website on Tuesday, October 31, 2023 at 9:00 a.m. ET.

On October 30, 2023 Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines, reported that it will be presenting three posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (Press release, Sonata Therapeutics, OCT 30, 2023, View Source [SID1234636471]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Network Medicines are drugs designed to modulate all the key cell types in networks of multifactorial diseases, thereby to halt or potentially reverse damage caused by such diseases. The majority of medicines are designed to disrupt or enhance single pathways in order to stop disease progression, but this approach often requires additional medications that target a different pathway, or combination therapy, to prevent drug resistance or drive response. In contrast, Sonata’s Network Medicines target pathways that change the complete dynamics of multifactorial diseases, resulting in more durable therapeutics and potentially better outcomes for patients.

One of the poster presentations will highlight one of Sonata’s Network Medicines, iART, that reprograms diseased cells to become the coordinators of cure for various indications including cancer. This Network Medicine has demonstrated profound efficacy across a variety of tumor models, representing an exclusive, broadly applicable off-the-shelf therapy for use in oncology.

The second poster presentation will highlight how SNT-20109, one of Sonata’s lead oncology programs, can induce protective immunity and an innovative form of enhanced-immunogenic cell death that has never been characterized in murine cancer models.

The third poster presentation will highlight SNT-4288, another of Sonata’s lead oncology programs, as a novel tool to induce ferroptosis for the treatment of sarcoma.

"As the former President of SITC (Free SITC Whitepaper), I’m thrilled to be back at the organization’s annual meeting as a member of Sonata’s leadership team and showcasing our novel Network Medicines approach that reprograms diseased cells to release curative signals resulting in durable disease resolution," said Francesco Marincola, M.D., Chief Scientific Officer of Sonata. "I look forward to connecting with my fellow leaders in the field of immuno-oncology and discussing the exciting potential of Sonata’s platform and programs."

The accepted abstracts are available online through the SITC (Free SITC Whitepaper) conference website: View Source

In addition, Dr. Marincola will co-chair the symposium "Synthetic Biology – Cell Therapy for Patients with Solid Cancer" on Friday, November 3 from 12:15-1:15 pm PT in Room 11AB of the conference venue. The symposium, sponsored by the Champalimaud Foundation, will highlight real-world challenges, outline solutions and foster collaborations to achieve the ultimate goal of significantly improving the survival of patients with cancer through synthetic biology.

Poster Presentations

Title: Sonata’s Proprietary Intrinsic Antigen Release Technology (iART) Drives In Situ Generation of Potent Anti-Tumor Immunity Across Warm and Cold Tumor Models
Date/Time: Friday, November 3, 2023, 12:00pm-1:30pm and 5:10pm-6:40pm PT
Abstract Number: 1403-B
Location: Ground Level, Exhibit Halls A and B1, San Diego Convention Center
Presenter: Ryan Shaler, Ph.D.

Title: SNT-20109 Induces Protective Immunity in the Murine Syngeneic Tumor Cell Line, CT26: A Dual Approach of Direct Cytotoxicity and Defined Immune Activation
Date/Time: Friday, November 3, 2023, 12:00pm-1:30pm and 5:10pm-6:40pm PT
Abstract Number: 1387
Location: Ground Level, Exhibit Halls A and B1, San Diego Convention Center
Presenter: Ryan Shaler, Ph.D.

Title: Exploring Novel Ferroptosis Inducer as a Promising Strategy for Sarcoma Treatment
Date/Time: Saturday, November 4, 2023, 9:00am-8:30pm PT
Abstract Number: 1442
Location: Ground Level, Exhibit Hall B, San Diego Convention Center
Presenter: Maria Cristina Munteanu, Ph.D.